C H Crane

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
    Henry Mok
    Department of Radiation Oncology, The University of Texas, M, d, Anderson Cancer Center, Houston, Texas, USA
    Radiat Oncol 6:63. 2011
  2. ncbi Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
  3. ncbi Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
  4. ncbi Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1145-51. 2006
  5. ncbi Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Oncol 26:S81-4. 2003
  6. ncbi The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:84-9. 2003
  7. ncbi Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment
    Christopher H Crane
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Semin Surg Oncol 21:265-70. 2003
  8. ncbi Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:4096-102. 2009
  9. ncbi Future chemoradiation strategies in pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:335-46. 2007
  10. ncbi The integration of chemoradiation in the care of patient with localized pancreatic cancer
    C H Crane
    Unit 97, Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, 1515, Holcombe Boulevard, Houston, 77030 Texas, USA
    Cancer Radiother 13:123-43. 2009

Detail Information

Publications89

  1. ncbi Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma
    Henry Mok
    Department of Radiation Oncology, The University of Texas, M, d, Anderson Cancer Center, Houston, Texas, USA
    Radiat Oncol 6:63. 2011
    ..Therefore, we performed a comprehensive dosimetric evaluation of IMRT compared to 3-dimensional conformal radiation therapy (3DCRT) in standard, preoperative treatment for rectal cancer...
  2. ncbi Concurrent capecitabine and upper abdominal radiation therapy is well tolerated
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Radiat Oncol 1:41. 2006
    ..Therefore, capecitabine and concurrent radiotherapy to the upper abdomen appears to be well tolerated. Capecitabine may serve as an alternative to bolus or infusional 5-FU during chemoradiation for upper gastrointestinal malignancies...
  3. ncbi Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
    ..Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen...
  4. ncbi Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:1145-51. 2006
    ..To study the safety of bevacizumab with capecitabine-based chemoradiotherapy...
  5. ncbi Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Oncol 26:S81-4. 2003
    ..These observations require further study, but are cause for concern when combining gemcitabine, radiotherapy, and celecoxib...
  6. ncbi The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:84-9. 2003
    ..To compare the outcome from preoperative chemoradiation (CXRT) and from radiation therapy (RT) in the treatment of rectal cancer in two large, single-institutional experiences...
  7. ncbi Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment
    Christopher H Crane
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Semin Surg Oncol 21:265-70. 2003
    ..However, more effective systemic therapies are needed, especially for patients who do not respond well to preoperative chemoradiation...
  8. ncbi Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:4096-102. 2009
    ..Secondary end points were toxicity, progression-free survival (PFS), and response rate (RR)...
  9. ncbi Future chemoradiation strategies in pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:335-46. 2007
    ..Herein, we discuss the relative merits of strategies that seek to improve outcome through these novel means and present recent data from novel strategies that will provide the background for future trials...
  10. ncbi The integration of chemoradiation in the care of patient with localized pancreatic cancer
    C H Crane
    Unit 97, Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, 1515, Holcombe Boulevard, Houston, 77030 Texas, USA
    Cancer Radiother 13:123-43. 2009
    ....
  11. ncbi Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    Christopher H Crane
    Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX
    J Clin Oncol 29:3037-43. 2011
    ..This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC)...
  12. ncbi The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer
    Christopher H Crane
    Department of Radiation Oncology, Unit 97, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Best Pract Res Clin Gastroenterol 20:365-82. 2006
    ..Herein, we discuss the rationale for the use of pre-operative chemoradiation in pancreatic cancer, the results of treatment, and future strategies to address the pattern of disease recurrence...
  13. ncbi Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:824-30. 2010
    ..We designed this Phase II trial to assess the efficacy and safety of the addition of bevacizumab to concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer...
  14. ncbi Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head
    C H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Gastrointest Cancer 30:123-32. 2001
    ..We hypothesized that dynamic intensity-modulated radiotherapy (IMRT) would protect normal tissues enough to allow the escalation of either the gemcitabine or radiotherapy dose in unresectable pancreatic cancer patients...
  15. ncbi Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer
    C H Crane
    Pancreatic Tumor Study Group, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Int J Pancreatol 29:9-18. 2001
    ..Gemcitabine and radiotherapy are a potent combination. A clinical assessment of the therapeutic ratio for locally advanced pancreatic cancer patients has not yet been reported...
  16. ncbi Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:517-24. 2003
    ..This article investigates the relationship between objective tumor response and sphincter preservation in low rectal carcinoma patients...
  17. ncbi Preoperative chemoradiation for locally advanced rectal cancer: emerging treatment strategies
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Oncology (Williston Park) 16:39-44. 2002
    ....
  18. ncbi Limitations of conventional doses of chemoradiation for unresectable biliary cancer
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 53:969-74. 2002
    ..To determine, in a retrospective review, the limitations of definitive chemoradiation in the treatment of patients with unresectable extrahepatic cholangiocarcinoma and generate testable hypotheses for future prospective clinical trials...
  19. ncbi Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    Christopher H Crane
    Pancreatic Tumor Study Group, Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 52:1293-302. 2002
    ..To retrospectively compare the toxicity and efficacy of concurrent gemcitabine-based chemoradiation with that of concurrent 5-fluorouracil (5-FU)-based chemoradiation in patients with unresectable pancreatic cancer...
  20. ncbi The role of intraoperative radiotherapy in pancreatic cancer
    Christopher H Crane
    Gastrointestinal Section, Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 97, Houston, TX 77030, USA
    Surg Oncol Clin N Am 12:965-77. 2003
    ....
  21. ncbi Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index
    C H Crane
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Semin Oncol 28:25-33. 2001
    ..Finally, the addition of radioprotectors may enable chemotherapy dose escalation, but safe escalation of the radiotherapy dose with newer techniques has not been established. Semin Oncol 28 (suppl 10):25-33...
  22. ncbi Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration
    T M Breslin
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Ann Surg Oncol 8:123-32. 2001
    ....
  23. ncbi Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents
    P W Pisters
    Pancreatic Tumor Study Group, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
    J Clin Oncol 18:860-7. 2000
    ....
  24. ncbi T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment
    N J Sanfilippo
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 51:176-83. 2001
    ..Future strategies must also include more effective systemic therapy...
  25. ncbi Neoadjuvant strategies for pancreatic cancer
    D B Evans
    University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 15:727-37; discussion 741-4, 747. 2001
    ..When given prior to surgery, chemoradiation is not delayed and patients found to have disease progression after chemoradiation are not subjected to an unnecessary laparotomy...
  26. ncbi Neoadjuvant therapy for resectable pancreatic cancer
    Chandrajit P Raut
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Surg Oncol Clin N Am 13:639-61, ix. 2004
    ..Future clinical trials for resectable pancreatic cancer will lead to progress only if the principles of multidisciplinary cancer care and quality assurance are incorporated into their design and conduct...
  27. ncbi Clinical benefit of palliative radiation therapy in advanced gastric cancer
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Acta Oncol 47:421-7. 2008
    ..Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of palliation with radiotherapy (RT)...
  28. ncbi Chemoradiation for adenocarcinoma of the anus
    Michael Papagikos
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
    Int J Radiat Oncol Biol Phys 55:669-78. 2003
    ....
  29. ncbi Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction
    Kazumasa Fujitani
    Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 444, P.O. Box 301402, Houston, TX 77230-1402, USA
    Ann Surg Oncol 14:1305-11. 2007
    ....
  30. ncbi Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction
    Kazumasa Fujitani
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Ann Surg Oncol 14:2010-7. 2007
    ....
  31. ncbi Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation
    Jeffrey D Wayne
    The Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 7:34-45. 2002
    ..This paper examines the factors pertinent to clinical trial design for resectable pancreatic cancer, and carefully reviews the existing data supporting adjuvant and neoadjuvant therapy for potentially resectable disease...
  32. ncbi Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome
    J A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:1237-44. 2005
    ....
  33. ncbi Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone
    Yerko Borghero
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, TX 77030, USA
    Ann Surg Oncol 15:3147-56. 2008
    ....
  34. ncbi Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer
    Tse Kuan Yu
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:1175-80. 2008
    ..To identify patterns of locoregional recurrence in patients treated with surgery and preoperative or postoperative radiotherapy or chemoradiation for rectal cancer...
  35. ncbi Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer
    Glenda G Callender
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:441-7. 2010
    ..At nearly 4 years' follow-up, no difference in outcome was observed. This study compares outcomes in a larger cohort of patients and reevaluates the original 26 patients after longer follow-up...
  36. ncbi Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 70:735-43. 2008
    ..We retrospectively compared treatment outcomes in patients treated with pancreaticoduodenectomy alone versus those who received additional adjuvant CRT...
  37. ncbi Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer
    Hee Chul Park
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 75:775-81. 2009
    ..To investigate whether symptom burden before and during preoperative chemoradiation therapy (CRT) for rectal cancer predicts for pathologic tumor response...
  38. ncbi Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy
    E P Tamm
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77070, USA
    Abdom Imaging 31:568-74. 2006
    ..Preoperative chemoradiation can potentially improve outcomes in patients with pancreatic cancer. This study addresses its effect on staging pancreatic cancer with multidetector computed tomography (MDCT)...
  39. ncbi Fatigue during preoperative chemoradiation for resectable rectal cancer
    X S Wang
    Pain Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 92:1725-32. 2001
    ..Based on identified predictors for fatigue, more active pain management before CXT/XRT and bowel management during CTX/XRT might reduce cancer-related fatigue in these patients...
  40. ncbi Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapy
    Valerie K Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:741-7. 2008
    ..To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients...
  41. ncbi Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course
    Michael P Herman
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 74:818-23. 2009
    ..Our goal was to determine the incidence, risk factors, and clinical course of SI fractures in patients treated with preoperative chemoradiation for rectal cancer...
  42. ncbi Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  43. ncbi Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  44. ncbi Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 66:762-71. 2006
    ..The pathologic response rate is comparable to our previous experience using protracted venous infusion 5-FU for LARC...
  45. ncbi Outcome after curative resection for locally recurrent rectal cancer
    Isabelle Bedrosian
    Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 444, Houston, Texas 77030, USA
    Dis Colon Rectum 49:175-82. 2006
    ..Preoperative carcinoembryonic antigen and an R0 resection margin were the only significant predictors of overall survival. p53, bcl-2, and ki-67 did not impact survival outcomes...
  46. ncbi Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery
    Michelle M Kim
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 71:167-72. 2008
    ....
  47. ncbi Pancreaticoduodenectomy with vascular resection: margin status and survival duration
    Jennifer F Tseng
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    J Gastrointest Surg 8:935-49; discussion 949-50. 2004
    ....
  48. ncbi Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy?
    Thomas A Aloia
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 204:347-55. 2007
    ..This study reexamined the frequency of delayed recovery and assessed other factors associated with adjuvant therapy administration after PD at a high-volume center...
  49. ncbi Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal
    John T Mullen
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 1402, USA
    Ann Surg Oncol 14:478-83. 2007
    ..For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice. The purpose of this study is to review our experience with salvage surgery in this group of patients...
  50. ncbi Pain and quality of life after treatment in patients with locally recurrent rectal cancer
    Nestor F Esnaola
    Department of Surgery, Pain Research Group, The University of Texas M D Anderson Cancer Center, Houston 77030 4009, USA
    J Clin Oncol 20:4361-7. 2002
    ..The purpose of this study was to assess the prevalence of posttreatment pain and QOL of patients with LRRC treated with nonsurgical palliation or resection and identify predictors of poor outcome...
  51. ncbi The optimization of dose delivery for intraoperative high-dose-rate radiation therapy using curved HAM applicators
    A Sam Beddar
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Radiother Oncol 78:207-12. 2006
    ..To determine the effect of the curvature of Harrison-Anderson-Mick applicators on the dose distribution in high-dose-rate intraoperative radiation therapy (HDR-IORT)...
  52. ncbi Radiotherapy for hepatocellular carcinoma: an overview
    Sunil Krishnan
    Division of Radiation Oncology, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 097, Houston, Texas 77030, United States
    Ann Surg Oncol 15:1015-24. 2008
  53. ncbi Long-term quality of life after radiotherapy for the treatment of anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Cancer 116:822-9. 2010
    ..Radiotherapy is the current standard of care for patients with localized squamous cell cancer of the anal canal. The goal of the current study was to evaluate long-term quality of life (QoL) in patients after this treatment...
  54. ncbi Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 23:3094-103. 2005
    ..To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center...
  55. ncbi Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 426, Houston, TX 77030, USA
    J Clin Oncol 26:3487-95. 2008
    ..We conducted a phase II trial of preoperative gemcitabine and cisplatin chemotherapy in addition to chemoradiation (Gem-Cis-XRT) and pancreaticoduodenectomy (PD) for patients with stage I/II pancreatic adenocarcinoma...
  56. ncbi Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head
    Douglas B Evans
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 26:3496-502. 2008
    ..We conducted a phase II trial to assess the outcomes of patients who received preoperative gemcitabine-based chemoradiation and pancreaticoduodenectomy (PD) for stage I/II pancreatic adenocarcinoma...
  57. ncbi Combined-modality treatment for operable pancreatic adenocarcinoma
    Peter W T Pisters
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Oncology (Williston Park) 19:393-404, 409; discussion 409-10, 412-6. 2005
    ..Many newer chemotherapeutic agents with efficacy in gastrointestinal cancers have yet to be investigated in the adjuvant and neoadjuvant settings...
  58. ncbi Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 77:60-5. 2010
    ..To retrospectively determine rates of toxicity, freedom from local progression, and survival in rectal cancer patients treated with reirradiation...
  59. ncbi Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis
    Prajnan Das
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 66:1378-83. 2006
    ....
  60. ncbi Staging, prognostic factors, and therapy of localized rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Curr Oncol Rep 11:167-74. 2009
    ..This article reviews recent studies on staging, prognostic factors, and therapy of localized rectal cancer...
  61. ncbi Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
    Dig Dis Sci 55:1098-105. 2010
    ..Upon further expansion and validation, these results may provide a biomarker-based understanding of heterogeneous clinical biology of patients with anal carcinoma...
  62. ncbi Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma
    Jason B Fleming
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Arch Surg 144:216-21. 2009
    ..To examine the influence of obesity, as measured by body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), on clinicopathologic factors and survival after pancreatectomy to treat adenocarcinoma...
  63. ncbi High-dose-rate remote afterloaders for intraoperative radiation therapy
    Song Gao
    Department of Radiation Physics at the University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    AORN J 86:827-36; quiz 837-40. 2007
    ....
  64. ncbi Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:2589-96. 2006
    ..Prognostic factors are inadequately defined for disease-free survival and overall survival in patients with LAPC who are receiving chemoradiation, so more definitive prognostic factors would be very useful for designing clinical trials...
  65. ncbi Conformal radiotherapy of the dominant liver metastasis: a viable strategy for treatment of unresectable chemotherapy refractory colorectal cancer liver metastases
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    Am J Clin Oncol 29:562-7. 2006
    ..CONCLUSIONS: Conformal RT to the dominant liver metastasis as palliative therapy for unresectable colorectal cancer liver metastases has an acceptable toxicity profile and may improve survival. This approach merits further exploration...
  66. ncbi Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy
    Gauri R Varadhachary
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1035-46. 2006
    ....
  67. ncbi Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 29:219-24. 2006
    ..To identify predictive factors for locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) in patients treated with chemoradiation and surgery for rectal cancer...
  68. ncbi Predictors and patterns of recurrence after definitive chemoradiation for anal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:794-800. 2007
    ..To evaluate patterns of locoregional failure, and predictors of recurrence and survival in patients treated with chemoradiation for anal cancer...
  69. ncbi Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma
    Pooja R Rohatgi
    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Cancer 107:1475-82. 2006
    ..Surgical pathology stage, in this setting, may serve as an intermediate endpoint for Phase II/III trials...
  70. ncbi Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1750-5. 2007
    ..The objective of this study was to identify predictive factors for pathologic complete response and tumor downstaging after preoperative chemoradiation for rectal cancer...
  71. ncbi Preoperative and adjuvant treatment of localized rectal cancer
    Prajnan Das
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Curr Oncol Rep 8:167-73. 2006
    ..The roles of newer agents, such as capecitabine, oxaliplatin, and bevacizumab, are also discussed, and other key issues in the treatment of localized rectal cancer are reviewed...
  72. ncbi Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer
    Pooja R Patel
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 110:989-95. 2007
    ..The authors hypothesized that presurgical (postCTRT) stage would also correlate better with patient outcome than the baseline stage...
  73. ncbi Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Chandrajit P Raut
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 246:52-60. 2007
    ..To better understand the impact of a microscopically positive margin (R1) on patterns of disease recurrence and survival after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma...
  74. ncbi Current treatment for localized anal carcinoma
    Prajnan Das
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Opin Oncol 19:396-400. 2007
    ..Chemoradiation represents the standard of care for most patients with localized squamous cell carcinoma of the anal canal. This article reviews randomized trials and recent studies on chemoradiation for anal cancer...
  75. ncbi Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer
    Donghui Li
    Department of Gastrointestinal Medical Oncology Unit 426, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 24:1720-8. 2006
    ..Our goal was to determine whether single nucleotide polymorphisms (SNPs) in DNA repair genes influence the clinical outcome of pancreatic cancer...
  76. ncbi Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy
    Sunil Krishnan
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 110:47-55. 2007
    ....
  77. ncbi Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases
    Michael J Overman
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77005, USA
    Clin Colorectal Cancer 7:338-42. 2008
    ..Such trimodality therapy can result in durable palliation of symptoms and long-term survival for patients with recurrent CRC involving the duodenum and pancreas, even when other metastases are present...
  78. ncbi Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:3953-8. 2006
    ..We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points...
  79. ncbi Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme
    Luka Milas
    Department of Experimental Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:15-24. 2003
    ..Thus, selective targeting of COX-2 may potentially improve radiotherapy, chemotherapy, or chemoradiotherapy--a therapeutic strategy that is currently being tested in clinical trials...
  80. ncbi Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes
    Cielito C Reyes-Gibby
    Department of Epidemiology, Division of Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Pain Symptom Manage 38:894-902. 2009
    ..23, 95% CI=1.4, 4.7) for severe pain relative to the AA genotypes. We provide preliminary evidence of the role of IL-8 in the severity of pain in pancreatic cancer patients. Additional studies are needed in larger cohorts of patients...
  81. ncbi Palliative and postoperative radiotherapy in biliary tract cancer
    O Kenneth Macdonald
    University of Texas at Houston Medical School, 6431 Fannin, Houston, TX 77030, USA
    Surg Oncol Clin N Am 11:941-54. 2002
    ..Novel approaches, including neoadjuvant chemoradiotherapy combined with OLT, and escalated conformal irradiation, seem to be promising and warrant further investigation...
  82. ncbi In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104
    Christopher H Crane
    Int J Radiat Oncol Biol Phys 58:1009; author reply 1009-10. 2004
  83. ncbi Improving soft-tissue contrast in four-dimensional computed tomography images of liver cancer patients using a deformable image registration method
    He Wang
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:201-9. 2008
    ..To investigate a deformable image registration method to improve soft-tissue contrast in four-dimensional (4D) computed tomography (CT) images of the liver...
  84. ncbi Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?
    Christopher H Crane
    J Clin Oncol 22:2978-81. 2004
  85. ncbi Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas
    Adrian A Wong
    The University of Texas Medical School at San Antonio, San Antonio, Texas, USA
    Am J Clin Oncol 28:227-33. 2005
    ....
  86. ncbi Chemotherapy for pancreatic cancer
    Christopher H Crane
    N Engl J Med 350:2713-5; author reply 2713-5. 2004
  87. ncbi The promises and potential pitfalls of organ preservation for locally advanced rectal cancer
    Christopher H Crane
    Ann Surg Oncol 13:288-90. 2006
  88. ncbi Will identifying or targeting altered marker expression in response to cytotoxic therapy be of prognostic or therapeutic value?
    Christopher H Crane
    J Clin Oncol 21:3381-2. 2003
  89. ncbi The added value of multidisciplinary care for patients with pancreatic cancer
    Douglas B Evans
    Ann Surg Oncol 15:2078-80. 2008